Great Point Partners, a Greenwich-based healthcare-focused private investment firm, has acquired a majority stake in Lenis Group, a Slovenia-based commercialization and distribution partner for niche and specialty prescription medicines across Central and Eastern Europe. The investment is intended to support Lenis as it expands its regional footprint and broadens access to specialty therapies in markets that can be operationally complex due to varying regulatory, reimbursement, and distribution requirements.
Founded in 2008, Lenis works with biotechnology and pharmaceutical companies across the CEE region across the full product lifecycle, including early access and pre-launch support, commercial launch execution, growth initiatives, and mature lifecycle management. The company positions itself as a full-service partner with capabilities spanning market access and reimbursement, regulatory expertise, medical functions, and marketing execution, supported by direct presence in local CEE markets and cross-functional teams embedded across its operating footprint.
Great Point Partners said Lenis has built a reputation for compliance and quality standards while serving as a key stakeholder in maintaining the continuity of supply for critical therapies. Lenis works closely with healthcare institutions and professionals, regulators, NGOs, and patient organizations, reflecting the importance of coordinated engagement in ensuring the availability of specialized medicines across multiple countries.
As part of the transaction, Lenis’s existing management team plans to remain involved in day-to-day operations. Great Point Partners said it is also committing resources to accelerate Lenis’s expansion strategy and to strengthen further senior leadership, including appointing Michel Vounatsos, formerly the Chief Executive Officer of Biogen, as Board Chairman.
The announcement also highlighted recent commercial momentum, citing Gilead Sciences’ decision to extend its relationship with Lenis and to maintain Lenis as its exclusive full-service distributor across eight countries in the Adriatic region. The companies framed the continued partnership as a validation of Lenis’s operational model and its ability to support specialty products across multiple markets.
Great Point Partners said the investment aligns with its focus on healthcare services and supply chain-related businesses, and positions Lenis to deepen its role as a regional partner for market access, promotion, and distribution as pharmaceutical companies seek scalable routes to reach patients across Central and Eastern Europe.
KEY QUOTES:
“When selecting a partner for this next stage in our development, we sought a group that could bring true value and share the support of the mission that we are deeply committed to. Great Point Partners’ unrivaled healthcare expertise made them the clear choice. Our entire team is excited about what we will accomplish together as we continue expanding into new markets across the CEE region and beyond.”
Branko Huč, Founder of Lenis Group
“Every country deserves a strong and reliable pharmaceutical supply chain, and there is no company with the track record, expertise and unparalleled quality and compliance standards in the CEE that matches that of the Lenis Group. We look forward to partnering with the Lenis team to firmly establish the Company as the go-to player for market access, promotion and distribution of pharmaceutical products in the region, leveraging its extensive KOL network and therapeutic-area expertise.”
David Slattery, Principal And Head Of The Firm’s London Office, Great Point Partners
